



Attorneys at Law

RECEIVED
CENTRAL FAX CENTER

JUN 30 2006

Suite 2800 1100 Peachtree St.
Atlanta GA 30309-4530
t 404 815 6500 f 404 815 6555
www.KilpatrickStockton.com

June 30, 2006

direct dial 404 745 2502
direct fax 404 541 3355
SBrosmore@KilpatrickStockton.com

FAX

RECIPIENT/ PHONE NO.	FAX NO.	COMPANY/ CITY, STATE, COUNTRY
Examiner Thomas Heard	571-273-8300	U.S. Patent and Trademark Office Washington, D.C.

Shirley E. Brosmore

FROM

18

PAGES (WITH COVER)

4341

REFERENCE NO

43170/286877

CLIENT/MATTER NO.

PLEASE CALL 404 815 6497 IF YOU HAVE DIFFICULTY WITH THIS TRANSMISSION.

CONFIDENTIALITY NOTE:

The information contained in this fax message is being transmitted to and is intended for the use of the individual named above. If the reader of this message is not the intended recipient, you are hereby advised that any dissemination, distribution or copy of this fax is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and destroy this fax message.

COMMENTS

In re Application of: Hembrough et al.

Serial No. 10/608,886

Filed: June 26, 2003

Title: Compositions and Methods Comprising Proteinase Activated Receptor Antagonists

Papers Submitted:

Amendment Transmittal

Amendment and Response to Restriction Requirement

TO BE COMPLETED BY KS OPERATIONS CENTER

TRANSMISSION RECEIPT DATE/TIME: _____

COMPLETED BY: _____

JOB CODE _____

ATLANTA AUGUSTA CHARLOTTE LONDON NEW YORK RALEIGH STOCKHOLM WASHINGTON WINSTON-SALEM

PATENTS

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re Application of:

Docket No. 05213-3041 (43170-286877)

HEMBROUGH ET AL.

Serial No. 10/608,886

Filed: June 26, 2003

For: COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR
ANTAGONISTSRECEIVED
CENTRAL FAX CENTER

JUN 30 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a paper in the above-identified application.

- ☒ Amendment and Response to Restriction Requirement.
☒ Applicant claims small entity status.
☒ No additional fee is required.
☐ The additional fee is calculated as shown below:

					SMALL ENTITY		OTHER THAN SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	20	MINUS	20=	0	x25	\$	x50	\$
INDEP.	1	MINUS	3=	0	x100	\$	x200	\$
FIRST PRESENTATION OF								
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS					+180	\$	+360	\$
TOTAL								
ADDITIONAL FEE						\$		\$

- ☐ A check in the amount of \$ is attached.
☐ Form PTO-2038 is attached, authorizing the charge of \$.
☒ The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16, or credit any overpayment, to Account No. 11-0855. A duplicate copy of this sheet is enclosed.

I hereby certify that this correspondence is being facsimile transmitted
to the United States Patent and Trademark Office (Fax No. 571-273-8300)
on June 30, 2006.

Shirley E. Brosmore
Shirley E. Brosmore - Reg. No. 56,167

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
Telephone: 404/815-6500

By: *Shirley E. Brosmore*
Shirley E. Brosmore, Agent for Applicant
Reg. No. 56,167

RECEIVED
CENTRAL FAX CENTER

JUN 30 2006

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
HEMBROUGH ET AL.)
)
Serial No. 10/608,886) Art Unit: 1654
)
Filed: June 26, 2003) Examiner: Heard, Thomas
)
For: COMPOSITIONS AND METHODS COMPRISING)
PROTEINASE ACTIVATED RECEPTOR)
ANTAGONISTS)

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated May 31, 2006, please amend the above-identified application as follows.

No additional fees are believed due, however, the Commissioner is hereby authorized to charge any additional fee and credit any refund to Deposit Account No. 11-0855.

Amendments to the Specification begin on page 2 of this paper.


Amendments to the Claims are reflected in the listing of claims, which begins on page 9 of this paper.

Amendments to the Abstract begin on page 13 of this paper.

Remarks begin on page 14 of this paper.

Conclusion begins on page 16 of this paper.

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office (Fax No. 571-273-8300) on June 30, 2006.


Shirley E. Brosmore - Reg. No. 56,167

2183496.1